WO2010143052A1 - Novel pharmaceutical compositions containing pregabalin - Google Patents
Novel pharmaceutical compositions containing pregabalin Download PDFInfo
- Publication number
- WO2010143052A1 WO2010143052A1 PCT/IB2010/001397 IB2010001397W WO2010143052A1 WO 2010143052 A1 WO2010143052 A1 WO 2010143052A1 IB 2010001397 W IB2010001397 W IB 2010001397W WO 2010143052 A1 WO2010143052 A1 WO 2010143052A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastro
- retentive
- floating
- pregabalin
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the present invention relates to a pharmaceutical composition, suitable for once daily dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof.
- Pregabalin or (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid, binds to the alpha- 2-delta subunit of a calcium channel and is related to the endogenous inhibitory neurotransmitter delta aminobutyric acid (GABA), which is involved in the regulation of brain neuronal activity.
- GABA inhibitory neurotransmitter delta aminobutyric acid
- Pregabalin exhibits anti-seizure activity, as discussed in U.S. Pat. No. 5,563,175 to R. B.
- Silverman et al. and is useful for treating, among other conditions, epilepsy, pain, physiological conditions associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, fibromyalgia, and various psychiatric disorders, including anxiety, depression, mania, and bipolar disorder.
- pregabalin has been approved for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunctive treatment for partial onset seizures in adults.
- Pregabalin is available as an immediate release (IR) formulation in capsules and is administered to patients' two- or three-times daily (BID or TID). Many patients receiving pregabalin or other drugs, which are, administered two or more times daily would likely benefit from once daily dosing.
- the convenience of once daily dosing generally improves patient compliance, especially for elderly patients and for patients taking multiple medications.
- Once per day dosing may also lessen or prevent potentially undesirable dose- related effects by reducing peak blood levels (C MAX ) and may also increase drug efficacy by increasing minimum plasma concentrations (C MIN )-
- pregabalin Once daily dosing of pregabalin, however, presents numerous challenges.
- Conventional extended release (ER) compositions are problematic for dosing because pregabalin is not absorbed uniformly in the gastrointestinal (GI) tract.
- GI gastrointestinal
- Clinical studies indicate that pregabalin is absorbed in the small intestine and the ascending colon in humans, but is poorly absorbed beyond the hepatic flexure. This suggests that the mean absorption window for pregabalin is, on average, about six hours or less and any drug release from a conventional ER dosage form beyond six hours would thus be wasted because the dosage form has traveled beyond the hepatic flexure.
- United States patent application no. 2007/0269511 Al discloses pregabalin formulations containing matrix forming agent and swelling agent wherein the matrix forming agent is polyvinyl acetate and polyvinylpyrrolidone, and the swelling agent is cross-linked polyvinylpyrrolidone.
- the present invention provides pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing.
- the pharmaceutical composition When administered as a solid dosage form, such as tablet, the pharmaceutical composition is retained in the stomach for a longer period of time than an IR dosage form. While it is retained in the stomach, the pharmaceutical composition continuously releases pregabalin for more than 8 hours, preferably more that 12 hours, still preferably more than 20 hours. Extending the period of time during which pregabalin is released in the stomach effectively widens the absorption window associated with IR dosing, thereby permitting once daily dosing.
- One aspect of the invention provides a pharmaceutical composition which is suitable for once daily dosing and includes an active pharmaceutical ingredient and excipients.
- the active pharmaceutical ingredient includes pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and the excipients include one or more water insoluble component.
- a further aspect of the invention provides a solid dosage form, such as a tablet, which is adapted for once daily oral dosing.
- the solid dosage form comprises the pharmaceutical composition described above.
- a further aspect of the invention provides a floating tablet, which is adapted for once daily oral dosing.
- the floating tablet comprises the pharmaceutical composition described above.
- An additional aspect of the invention provides a method of treating a condition or disorder in a subject that is responsive to pregabalin.
- the method includes orally administering to the subject once per day the pharmaceutical composition described above.
- Fig. 1 shows dissolution profiles of the pharmaceutical compositions according to the present invention in 900 ml, 0.06 N HCl using USP type 2 apparatus at 50 rpm.
- the present invention provides the pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing. '
- the present invention provides a pharmaceutical composition, which is suitable for once daily dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and the excipients.
- the present invention provides a pharmaceutical composition which is suitable for once daily dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component.
- the present invention provides a pharmaceutical composition which is suitable for once daily dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component wherein pharmaceutical composition is retained in the stomach of subject following oral dosing for about 0 to 24 hours.
- the present invention provides a pharmaceutical composition which is suitable for once daily dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component wherein the pregabalin is released over a period of time that is about 0 to 24 hours.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component wherein pharmaceutical composition floats as soon as contacting biological and/or aqueous fluids and remains in floating state for more than 3 hours, still preferably for more than 6 hours, still preferably for more than 12 hours, still preferably for more than 18 hours, still preferably for more than 24 hours.
- the present invention provides a pharmaceutical composition which is suitable for once daily dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component wherein the pharmaceutical composition can be bio-equivalent to an immediate release formulation comprising pregabalin, lactose monohydrate, maize starch, and talc.
- the present invention provides a solid dosage form, such as a tablet, which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component.
- the water insoluble components includes but are not limited to water insoluble polymers selected from group ethyl cellulose, cellulose acetate, cellulose acetate phthalate, polymethyacrylates, calcium silicates and combinations thereof and the like; the waxes selected from hydrogenated castor oil, hydrogenated vegetable oil, bees wax, carnauba wax, microcrystalline wax, ozocarite, fatty acid esters such as glyceryl monostearate; glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, zein, and combination thereof and the like.
- the most preferred water insoluble component is combination of ethylcellulose and hydrogenated castor oil.
- the present invention provides a solid dosage form, such as a tablet, which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and water insoluble component wherein water insoluble component is combination of ethylcellulose and hydrogenated castor oil.
- the present inventors have surprisingly found that the ratio of ethyl cellulose to hydrogenated castor oil is critical for preparing a gastro-retentive floating tablet suitable for once daily oral dosing comprising pregabalin wherein the floating and release of preagabalin in controlled manner is achieved by combination of ethyl cellulose and hydrogenated castor oil.
- Such gastro-retentive floating tablets floats as soon as contacting biological and/or aqueous fluids and remains in floating state for more than 3 hours, still preferably for more than 6 hours, still preferably for more than 12 hours, still preferably for more than 18 hours, still preferably for more than 24 hours wherein the weight ratio of ethyl cellulose to hydrogenated castor oil is from about 0.1 :10 to about 10:0.1, preferably from about 0.5: 10 to about 10:0.5, most preferably from about 1 :5 to 5: 1.
- the present inventors have further found that also the ratio of ethyl cellulose to polyethylene glycol is critical for preparing a gastro-retentive floating tablet suitable for once daily oral dosing comprising pregabalin wherein the floating and release of preagabalin in controlled manner is achieved by combination of ethyl cellulose and polyethylene glycol.
- Such gastro-retentive floating tablets floats as soon as contacting biological and/or aqueous fluids and remains in floating state for more than 3 hours, still preferably for more than 6 hours, still preferably for more than 12 hours, still preferably for more than 18 hours, still preferably for more than 24 hours wherein the weight ratio of ethyl cellulose to polyethylene glycol is from about 0.1 :10 to about 10:0.1, preferably from about 0.5: 10 to about 10:0.5, most preferably from about 1 :5 to 5:1.
- the present invention provides a gastro-retentive floating tablet adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients wherein the tablet exhibits in vitro release of pregabalin not less than 30% after 4 hours.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients wherein the tablet exhibits in vitro release of pregabalin not less than 40% after 8 hours.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients wherein the tablet exhibits in vitro release of pregabalin not less than 50% after 12 hours.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients wherein the tablet exhibits in vitro release of pregabalin not less than 70% after 16 hours.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients wherein the tablet exhibits in vitro release of pregabalin not less than 85% after 24 hours.
- the water soluble components include but are not limited to polyethylene glycol, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, vinyl acetate copolymers, polysaccharides as alginates, xanthan gum, Chitosan, carrageenan, dextran and the like, polyalkylene oxides as polyethylene oxide and the likes, methaacrylic acid copolymers, maleic anhydride/methyl vinyl ether copolymers, carbomers and the like.
- the most preferred water-soluble component is polyethylene glycol.
- the present invention provides a gastro-retentive floating tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and combination of ethylcellulose and polyethylene glycol.
- the present invention provides a gastro-retentive floating tablet adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and combination ethyl cellulose and polyethylene glycol wherein weight ratio of ethyl cellulose to polyethylene glycol is from about 0.1 :10 to about 10:0.1, preferably from about 0.5:10 to about 10:0.5, most preferably from about 1 :5 to 5:1.
- the present invention provides a floating tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component.
- present invention provides a gastro-retentive floating tablet adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component wherein the tablet is capable of floating for 0 to 24 hours.
- present invention provides a gastro-retentive floating tablet adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component wherein the tablet is capable of floating for more that 20 hours.
- the present invention provides a gastro-retentive floating tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and water insoluble component wherein the water insoluble component comprises of combination of ethylcellulose and hydrogenated castor oil.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and a combination of ethyl cellulose and hydrogenated castor oil; wherein weight ratio of ethyl cellulose to hydrogenated castor oil is from about 0.1 :10 to about 10:0.1, preferably from about 0.5:10 to about 10:0.5, most preferably from about 1:5 to 5:1.
- the present invention provides a gastro-retentive floating tablet which is adapted for once daily oral dosing comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and a combination of ethyl cellulose and hydrogenated castor oil wherein said combination of ethyl cellulose and hydrogenated castor oil is present from about 1 % w/w to about 80% w/w of the composition.
- the present invention provides a gastro-retentive floating bi-layer tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, wherein both the floating layer and the release controlling layer comprises of same one or more water insoluble component.
- the present invention provides a gastro-retentive floating bi-layer tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, wherein the floating layer and the release controlling layer both prepared of same composition comprising a combination of ethylcellulose and hydrogenated castor oil.
- the present invention provides a gastro-retentive floating bi-layer tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, wherein the floating layer comprises of gas entrapping swelling system and release controlling layer comprises of a combination one or more water insoluble component.
- the present invention provides a gastro-retentive floating bi-layer tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, wherein the floating layer comprises of gas entrapping swelling system comprises of sodium bicarbonate, sodium alginate, microcrystalline cellulose and release controlling layer comprises of a combination ethylcellulose and hydrogenated castor oil.
- the present invention provides a gastro-retentive floating tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more pharmaceutically acceptable excipients wherein tablet has friability below 1% w/w.
- the present invention provides a process of preparing a pharmaceutical composition
- a pharmaceutical composition comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble components wherein process can be selected from direct compression, dry granulation, wet granulation and melt granulation.
- the present invention provides a process of preparing gastro-retentive floating tablet comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, one or more water insoluble component wherein the water insoluble component is combination of ethylcellulose hydrogenated castor oil prepared by melt granulation technique.
- the present invention provides a method of treating a condition or disorder in a subject that is responsive to pregabalin the method comprising administering subject once daily pharmaceutical composition comprising pregabalin, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, and one or more water insoluble component.
- the method includes orally administering to the subject once per day the pharmaceutical composition described above.
- the dosage forms of the present invention typically contain 25 to 900 mg pregabalin as base.
- the dosage forms of the invention optionally may comprise pharmaceutically acceptable complexes, salts, polymorphs, hydrates, solvates, enantiomers or racemates of pregabalin.
- “Pharmaceutical composition” refers to the combination of one or more drug substances and one or more excipients.
- Drug product refers to a pharmaceutical composition that is administered to a subject in need of treatment and generally may be in the form of tablets, capsules, sachets containing powder or granules and the like.
- sustained in the stomach or Gastro-retentive when used in connection with a pharmaceutical composition or dosage form, means that at least a portion of the dosage form remains in a subject's stomach following oral administration for about three or more hours, which is substantially longer than the average residence time of a corresponding IR dosage form. While it is retained in the stomach, the dosage form continuously releases the drug.
- Release when used in connection with a pharmaceutical composition or dosage form, refers to the portion of the drug substance that leaves the dosage form following contact with an aqueous environment. Unless otherwise indicated, the quantity of drug released from a dosage form is measured by dissolution testing in 900 ml, 0.06N HCl using apparatus USP type 2 at 50 rpm.
- compositions of the present invention can also include other materials such as binders, diluents, anti-adherents, glidants and lubricants.
- Binders may be, for example, starch, sugars, gums, low molecular weight hydroxypropyl methylcellulose, povidone, hydroxypropyl cellulose, hydroxyethyl cellulose or the like.
- Diluents may be, for example, any pharmaceutically acceptable, non-toxic diluent. Particular examples include lactose, dextrose, sucrose, maltose, microcrystalline cellulose, starch, calcium hydrogen phosphate, mannitol and the like.
- Anti-adherents may be, for example, silicon-containing compounds such as silicon dioxide, magnesium trisilicate, talc and the like.
- Glidants include, but are not limited to, silicon dioxide; magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate, calcium silicate, magnesium silicate, colloidal silicon dioxide, silicon hydrogel and the like.
- Lubricants may be, for example, talc, magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, sodium benzoate or the like.
- Antiadherents and Glidants may be, for example, colloidal silicon dioxide, talc or the like.
- Solid oral dosage forms of the present invention may be prepared by any conventional techniques for example dry granulation, direct compression, wet granulation, melt granulation and extrusion-spheronization.
- Bi-layer floating tablet non-gas generating or non-swelling floating layer
- the bi-layer tablets were prepared using formula as described in Table No. 1.
- the manufacturing process used is as follows: A] Preparation of controlled release granules
- the ethylcellulose and Hydrogenated castor oil were sieved and mixed thoroughly. This mixture was lubricated using magnesium stearate.
- the bi-layer tablets were prepared using 21.O x 11.0 mm oval shaped, standard concave punches suitable for tablet compression machine.
- Bi-layer floating tablet gas generating or swelling floating layer
- the bi-layer tablets were prepared using formula as described in Table No. 3 the manufacturing process used was as follows:
- the Hydrogenated castor oil was melted at temperature about 90°C. Further pregabalin or mixture of pregabalin and part of Ethyl cellulose was sieved and mixed with melted hydrogenated castor oil. Above mixture is cooled with stirring and sieved to obtain granules. Obtained granules were mixed with ethylcellulose. This mixture was lubricated using magnesium stearate.
- the Sodium Bicarbonate, Sodium Alginate and Microcrystalline Cellulose were sieved and mixed thoroughly.
- the bi-layer tablets were prepared using 21.0 x 11.0 mm oval shaped, standard concave punches suitable for tablet compression machine.
- the tablets obtained above were tested for dissolution in 900 ml 0.06 N HCL using USP II (Paddle) apparatus at 50 rpm at 37 0 C + 0.5.
- the results obtained are given in Table No. 4
- the floating tablets were prepared using formula as described in table No. 5 the manufacturing process used was as follows:
- the Hydrogenated castor oil was melted at temperature about 90°C. Further pregabalin or mixture of pregabalin and part of Ethyl cellulose was sieved and mixed with melted hydrogenated castor oil. Above mixture is cooled with stirring and sieved to obtain granules. Obtained granules were mixed with ethylcellulose and hydrogenated castor oil (if applicable). This mixture was lubricated using magnesium stearate. The tablets were prepared using suitable tablet compression machine.
- the floating tablets were prepared using formula as described in table No. 7 the manufacturing process used was as follows:
- Preagabalin and intregranular quantity of ethyl cellulose, PEG 6000 were sieved and mixed. Sufficient quantity of ethanol was added above mixture and granules were prepared. Obtained granules were dried and sieved. Remaining quantity of ethyl cellulose, PEG 6000 was added to above granules mixed. This mixture was lubricated using magnesium Stearate. The tablets were prepared using suitable tablet compression machine.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2765172A CA2765172A1 (en) | 2009-06-12 | 2010-06-10 | Novel pharmaceutical compositions containing pregabalin |
RU2012100709/15A RU2012100709A (en) | 2009-06-12 | 2010-06-10 | NEW PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN |
EP10740703.3A EP2440190A1 (en) | 2009-06-12 | 2010-06-10 | Novel pharmaceutical compositions containing pregabalin |
AU2010258345A AU2010258345A1 (en) | 2009-06-12 | 2010-06-10 | Novel pharmaceutical compositions containing pregabalin |
MX2011013440A MX2011013440A (en) | 2009-06-12 | 2010-06-10 | Novel pharmaceutical compositions containing pregabalin. |
US12/818,060 US20110135723A1 (en) | 2009-06-12 | 2010-06-17 | Pharmaceutical compositions containing pregabalin |
ZA2011/09511A ZA201109511B (en) | 2009-06-12 | 2011-12-22 | Novel pharmaceutical compositions containing pregabalin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1386/CHE/2009 | 2009-06-12 | ||
IN1386CH2009 | 2009-06-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/818,060 Continuation US20110135723A1 (en) | 2009-06-12 | 2010-06-17 | Pharmaceutical compositions containing pregabalin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010143052A1 true WO2010143052A1 (en) | 2010-12-16 |
Family
ID=42813244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/001397 WO2010143052A1 (en) | 2009-06-12 | 2010-06-10 | Novel pharmaceutical compositions containing pregabalin |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110135723A1 (en) |
EP (1) | EP2440190A1 (en) |
AU (1) | AU2010258345A1 (en) |
CA (1) | CA2765172A1 (en) |
MX (1) | MX2011013440A (en) |
RU (1) | RU2012100709A (en) |
WO (1) | WO2010143052A1 (en) |
ZA (1) | ZA201109511B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2389935A1 (en) * | 2010-05-25 | 2011-11-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-Release oral Solution Formulations of Pregabalin |
WO2011151708A1 (en) | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
WO2012035559A3 (en) * | 2010-09-17 | 2012-06-28 | Panacea Biotec Ltd | Sustained release pharmaceutical compositions comprising pregabalin |
CN104546817A (en) * | 2014-12-25 | 2015-04-29 | 北京华禧联合科技发展有限公司 | Pregabalin sustained release preparation |
WO2015114509A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Stabilized gastroretentive tablets of pregabalin |
EP3375438A4 (en) * | 2017-02-01 | 2020-03-04 | GL Pharmtech Co., Ltd. | Oral sustained-release triple tablet containing pregabalin |
US11974974B2 (en) | 2019-07-03 | 2024-05-07 | Alvogen, Inc. | Controlled-release tablets, method of making, and method of use thereof |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2809303A1 (en) | 2012-01-30 | 2014-12-10 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
EP2809304A1 (en) | 2012-01-30 | 2014-12-10 | Ranbaxy Laboratories Limited | Gastroretentive tablets |
US9861585B2 (en) | 2012-10-16 | 2018-01-09 | Sun Pharmaceutical Industries Limited | Osmotic floating tablets |
KR102221846B1 (en) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | Pharmaceutical composition of pregabalin with improved stability and method for preparing thereof |
CN113577036B (en) * | 2021-05-31 | 2023-04-04 | 石药集团欧意药业有限公司 | Pregabalin gastric floating sustained release tablet and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563175A (en) | 1990-11-27 | 1996-10-08 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
WO2007048223A2 (en) * | 2005-10-25 | 2007-05-03 | Pharmascience Inc. | A gastric retention drug delivery system |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
US20070269511A1 (en) | 2005-11-02 | 2007-11-22 | Warner-Lambert Company Llc | Solid pharmaceutical compositions containing pregabalin |
WO2009066325A1 (en) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10014588A1 (en) * | 2000-03-27 | 2001-10-04 | Basf Ag | Sustained-release oral dosage form that floats in gastric fluid includes a blend of polyvinyl acetate and polyvinylpyrrolidone |
-
2010
- 2010-06-10 WO PCT/IB2010/001397 patent/WO2010143052A1/en active Application Filing
- 2010-06-10 RU RU2012100709/15A patent/RU2012100709A/en unknown
- 2010-06-10 EP EP10740703.3A patent/EP2440190A1/en not_active Withdrawn
- 2010-06-10 CA CA2765172A patent/CA2765172A1/en not_active Abandoned
- 2010-06-10 MX MX2011013440A patent/MX2011013440A/en not_active Application Discontinuation
- 2010-06-10 AU AU2010258345A patent/AU2010258345A1/en not_active Abandoned
- 2010-06-17 US US12/818,060 patent/US20110135723A1/en not_active Abandoned
-
2011
- 2011-12-22 ZA ZA2011/09511A patent/ZA201109511B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563175A (en) | 1990-11-27 | 1996-10-08 | Northwestern University | GABA and L-glutamic acid analogs for antiseizure treatment |
US20070184104A1 (en) * | 2001-10-25 | 2007-08-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
WO2007048223A2 (en) * | 2005-10-25 | 2007-05-03 | Pharmascience Inc. | A gastric retention drug delivery system |
US20070269511A1 (en) | 2005-11-02 | 2007-11-22 | Warner-Lambert Company Llc | Solid pharmaceutical compositions containing pregabalin |
WO2009066325A1 (en) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2389935A1 (en) * | 2010-05-25 | 2011-11-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-Release oral Solution Formulations of Pregabalin |
TR201005241A1 (en) * | 2010-05-25 | 2012-01-23 | Sanovel �La� San. Ve T�C. A.�. | Pregabalin solution formulation for controlled release. |
WO2011151708A1 (en) | 2010-06-01 | 2011-12-08 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
WO2012035559A3 (en) * | 2010-09-17 | 2012-06-28 | Panacea Biotec Ltd | Sustained release pharmaceutical compositions comprising pregabalin |
WO2015114509A1 (en) | 2014-01-28 | 2015-08-06 | Ranbaxy Laboratories Limited | Stabilized gastroretentive tablets of pregabalin |
CN104546817A (en) * | 2014-12-25 | 2015-04-29 | 北京华禧联合科技发展有限公司 | Pregabalin sustained release preparation |
EP3375438A4 (en) * | 2017-02-01 | 2020-03-04 | GL Pharmtech Co., Ltd. | Oral sustained-release triple tablet containing pregabalin |
US11974974B2 (en) | 2019-07-03 | 2024-05-07 | Alvogen, Inc. | Controlled-release tablets, method of making, and method of use thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2765172A1 (en) | 2010-12-16 |
EP2440190A1 (en) | 2012-04-18 |
RU2012100709A (en) | 2013-07-20 |
US20110135723A1 (en) | 2011-06-09 |
ZA201109511B (en) | 2012-09-26 |
AU2010258345A1 (en) | 2012-01-19 |
MX2011013440A (en) | 2012-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110135723A1 (en) | Pharmaceutical compositions containing pregabalin | |
JP5816091B2 (en) | Sodium oxybate immediate release dosage form | |
FI85439B (en) | Method for the production of an orally administered pharmaceutical preparation offering the possibility of controlled release | |
EP2217217B1 (en) | Controlled release pharmaceutical compositions of pregabalin | |
ES2606463T3 (en) | Combination of levodopa / carbidopa immediate release and controlled release dosage forms | |
ES2649063T3 (en) | Pharmaceutical formulations containing rifaximin, procedures for obtaining it and method of treatment of intestinal disease | |
DK2605757T3 (en) | Nalbuphine-based formulations and applications thereof | |
CA2628200A1 (en) | Solid pharmaceutical compositions containing pregabalin | |
KR20080059409A (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties | |
WO2006094737A2 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
EP2575798A1 (en) | Gastroretentive dosage forms of gaba analogs | |
KR101156054B1 (en) | A stable and control-released pharmaceutical composition comprising eperisone | |
ES2865278T3 (en) | Amantadine to improve gait in multiple sclerosis | |
EP2726064B1 (en) | Controlled release oral dosage form comprising oxycodone | |
US10632077B2 (en) | Pregabalin-containing, oral sustained-release triple layer tablet | |
ES2317450T3 (en) | FORMULATION OF CONTROLLED RELEASE OF VALPROIC ACID AND ITS DERIVATIVES. | |
JP2010511023A (en) | Memantine formulation | |
US20100310652A1 (en) | Coated extended release pharmaceutical compositions of levetiracetam | |
EP1225888A2 (en) | Sustained-release formulations for treating cns-mediated disorders | |
JP2009525953A (en) | Sustained release formulation of divalproic acid and its derivatives | |
US11007153B2 (en) | Pregabalin-containing, high swellable, sustained-release triple layer tablet | |
WO2014167439A1 (en) | Modified release pharmaceutical compositions of topiramate or salts thereof | |
US8962020B2 (en) | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10740703 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2765172 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010258345 Country of ref document: AU Ref document number: 2010740703 Country of ref document: EP Ref document number: MX/A/2011/013440 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012100709 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010258345 Country of ref document: AU Date of ref document: 20100610 Kind code of ref document: A |